*Mycobacterium tuberculosis*, the causative agent of tuberculosis (TB), has plagued mankind for centuries and is one of the world's deadliest infectious diseases. In 2014, 9.6 million patients were diagnosed with TB infection and ∼1.5 million people died.^[@ref1]^ Although the mortality rate has dropped by 47% since the 1990s, the emergence of multidrug resistant (MDR-TB) and extremely drug resistant (XDR-TB) strains has complicated our ability to control the disease. According to the World Health Organization (WHO), approximately 480,000 people developed MDR-TB in 2014 and the cure rate of those patients was only 50%.^[@ref1]^ Resistant strains are not susceptible to the standard drugs, and although MDR-TB is treatable using second-line drugs, such treatments are costly, toxic, and/or not readily available. Consequently, there is an urgent need for the development of new antitubercular therapies that are effective against resistant as well as persistent forms of tuberculosis. Ideally, new drugs should target essential pathways in *M. tuberculosis* that are not currently targeted by first- and second-line drugs.

The type I signal peptidase (SPase I), also known as the leader peptidase (LepB), is a key enzyme involved in protein secretion via the general secretion (Sec) pathway and is a potential drug target for tuberculosis.^[@ref2]^ Approximately 20% of all bacterial proteins synthesized are secreted, and they play vital roles in numerous processes, including nutrient uptake, pathogenicity, environmental response, resuscitation, cell wall biogenesis, and respiration.^[@ref3]^ The Sec pathway is highly conserved in bacteria and is the primary route involved in the export of proteins across the cytoplasmic membrane. LepB catalyzes the cleavage of the N-terminal signal peptide from preproteins during or shortly after translocation, releasing the mature protein into the extracellular space.^[@ref3]^*M. tuberculosis* has a single LepB homologue, which is essential for cell viability.^[@ref2]^ Inhibiting LepB would prevent cleavage of the signal peptide from the preprotein; consequently, the proteins destined to be secreted would remain membrane bound.^[@ref4]−[@ref8]^ Inhibition of LepB would also interfere with the translocation of proteins critical for various cellular processes and could ultimately lead to cell death.

Bacterial SPases are membrane-bound endopeptidases belonging to the serine protease family S26^[@ref9]^ and are structurally and mechanistically distinct from their eukaryotic counterparts. Eukaryotic SPases utilize a catalytic triad composed for Ser-His-Asp residues, whereas bacterial SPases I use a unique Ser-Lys catalytic dyad mechanism.^[@ref10],[@ref11]^ In the proposed mechanism, the serine hydroxyl group from the bacterial SPase attacks the peptide substrate from the *si*-face rather than the *re*-face as seen in eukaryotic SPase.^[@ref11]^ Such differences can be exploited for the design of selective inhibitors of bacterial SPase I and should limit off-target toxicity. In addition to their unique catalytic mechanism and essentiality, another attractive feature of type I SPase as a potential drug target is the location of the catalytic domain on the extracellular surface, suggesting increased accessibility. Target-based whole cell screening strategies have been implemented in the identification of compounds targeting known biological targets within a cellular context.^[@ref12],[@ref13]^ Such strategies utilize conditional mutant strains exhibiting either reduced or enhanced expression levels of a particular target. One advantage of this strategy over a biochemical based approach is that it allows for the identification of active inhibitors at a cellular level. Biochemical screening campaigns often lead to the identification of potent enzyme inhibitors, which lack whole cell activity due to poor penetration, rapid efflux, and/or inactivation. To examine the potential of LepB as an antitubercular target and to identify inhibitors potentially targeting protein secretion, we developed and implemented a target-based whole cell screen using a strain engineered with reduced expression of the sole, essential LepB homologue. Presented here are the results of our screen of 72,000 compounds against the wild-type (wt) and *lepB* underexpressing (LepB-UE) strains of *M. tuberculosis*. The screening campaign led to the identification of the phenylhydrazone series (PHY), which are more potent against the LepB-UE strain than the wt *M. tuberculosis*.

Results and Discussion {#sec2}
======================

We are interested in LepB, and more generally the secretory pathway and the secretome, as a drug target for novel antitubercular agents.^[@ref2]^ Therefore, we were interested in developing a target-based whole cell screen that could capture both inhibitors acting on this mechanism while confirming potency against live bacteria.

Generation of the LepB underexpressing Strains {#sec2.1}
----------------------------------------------

We first needed to construct a hypomorph, in which LepB expression was reduced as much as possible but still allowing for robust growth. We predicted this would give us strains that would be hypersusceptible to LepB inhibition, but would remain amenable to screening. To achieve this, we needed to construct stable strains in which LepB expression was reduced. Although we had previously generated strains in which LepB expression was under the control of a regulatable promoter (tetracycline-inducible system), these strains were not sufficiently stable for use in a high-throughput screen because they accumulated mutations that removed the inducibility of the promoter.^[@ref2]^ We generated a number of strains in which the only functional LepB allele was under the control of various *M. tuberculosis* promoters in order to find a suitable strain ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

###### Strains and Plasmids Used in This Study

  strain or plasmid           description                                                                                      source or reference
  --------------------------- ------------------------------------------------------------------------------------------------ ---------------------
  plasmids                                                                                                                     
  pSM128                      promoter probe vector-L5 integrase, *lacZ*, Sm                                                   ([@ref39])
  pINT7                       pSM128 derivative lacking the *lacZ* gene                                                        ([@ref2])
  pCherry10                   P~G13~-mCherry in replicating vector, Hyg                                                        ([@ref42])
  pIKL-R1                     P~senX3~ in pSM128                                                                               ([@ref14])
  pTRP5                       P~trpE~ in pSM128                                                                                ([@ref15])
  pTRP7                       P~trpD~ in pSM128                                                                                ([@ref15])
  pLUSH5                      P~gln *E*~ in pSM128, Sm                                                                         ([@ref16])
  pHIP1                       P~Rv0251c~ in pSM128, Sm                                                                         this study
  pHIP2                       P~Rv2466c~ in pSM128, Sm                                                                         this study
  pHIP3                       P~Rv2745c~ in pSM128, Sm                                                                         this study
  pHIP4                       P~Rv2930~ in pSM128, Sm                                                                          this study
  pHIP5                       P~Rv0967~ in pSM128, Sm                                                                          this study
  pHIP6                       P~mbtI~ in pSM128, Sm                                                                            this study
  pUPPY1                      *P*~*senX3*~*-lepB* in integrating vector, L5 int, Sm                                            this study
  pUPPY2                      *P*~*trpE*~*-lepB* in integrating vector, L5 int, Sm                                             this study
  pUPPY3                      *P*~*trpD*~*-lepB* in integrating vector, L5 int, Sm                                             this study
  pUPPY5                      *P*~*gln *E**~*-lepB* in integrating vector, L5 int, Sm                                          this study
  pUPPY6                      P~Rv0251c~-*lepB* in integrating vector, L5 int, Sm                                              this study
  pUPPY7                      P~Rv2466c~-*lepB* in integrating vector, L5 int, Sm                                              this study
  pUPPY8                      P~Rv2745c~-*lepB* in integrating vector, L5 int, Sm                                              this study
  pUPPY9                      P~Rv2930~-*lepB* in integrating vector, L5 int, Sm                                               this study
  pUPPY10                     P~Rv0967~-*lepB* in integrating vector, L5 int, Sm                                               this study
  pUPPY11                     P~mbtI~-*lepB* in integrating vector, L5 int, Sm                                                 this study
  pUPPY13                     native *lepB* in integrating vector, L5 int, Sm                                                  this study
  pOPPY4                      P~hsp60-lepB~ in expression vector pSMT3, Hyg                                                    ([@ref14])
  *M. tuberculosis* strains                                                                                                    
  H37Rv                       wild-type                                                                                        ATCC 25618
  CHEAM3                      H37Rv pluspCherry10 \[P~G13~-mCherry, Hyg\]                                                      ([@ref19])
  SPAM13C                     chromosomal *lepB* Δ; integrated \[P~lepB~-*lepB*, L5 int, Sm\]; pCHERRY10 \[mCherry, Hyg\]      this study
  SPAM15C                     chromosomal *lepB* Δ; integrated \[P~gln *E*~-*lepB*, L5 int, Sm\]; pCHERRY10 \[mCherry, Hyg\]   this study
  SPAM17C                     chromosomal *lepB* Δ; integrated \[P~Rv2466c~-LepB, L5 int, Sm\]; pCHERRY10 \[mCherry, Hyg\]     this study
  SPAM18C                     chromosomal *lepB* Δ; integrated \[P~Rv2745c~-*lepB*, L5 int, Sm\]; pCHERRY10 \[mCherry, Hyg\]   this study
  SPAM19C                     chromosomal *lepB* Δ; integrated \[P~Rv2930~-*lepB*, L5 int, Sm\]; pCHERRY10 \[mCherry, Hyg\]    this study
  SPAM20C                     chromosomal *lepB* Δ; integrated \[P~senX3~-*lepB*, L5 int, Sm\]; pCHERRY10 \[mCherry, Hyg\]     this study
  SPAM22C                     chromosomal *lepB* Δ; integrated \[P~trpE~-*lepB*, L5 int, Sm\]; pCHERRY10 \[mCherry, Hyg\]      this study
  SPAM23C                     chromosomal *lepB* Δ; integrated \[P~trpD~-*lepB*, L5 int, Sm\]; pCHERRY10 \[mCherry, Hyg\]      this study
  LepB-OE                     H37Rv; pOPPY4 \[P~hsp60~-*lepB*,pSMT3,Hyg\]                                                      this study

We constructed recombinant strains by gene switching^[@ref17]^ and monitored both growth and the level of LepB mRNA. Expression of LepB from promoters P~Rv0251c~, P~Rv0967~, and P~mbtl~ did not result in viable strains. A reduction in LepB expression was seen with the remainder of the promoters tested, except P~gln*E*~ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Of note, expression from the native promoter at the L5 integration site was lower than in the wild-type strain; this phenomenon has been previously noted, in that general expression levels from promoters integrated at the L5 *att* site appear to be lower than in their native sites, possibly due to local effects such as supercoiling.^[@ref18]^

![Expression levels of LepB. *M. tuberculosis* strains were grown in 7H9-Tw-OADC. mRNA levels were determined by RT-qPCR, and the results are normalized to *sigA* transcripts. Data are the mean ± standard deviation of three replicates. Strains of *M. tuberculosis* expressing codon-optimized mCherry were wild-type H37Rv (CHEAM3), and strains expressing LepB under the control of different promoters were SPAM13C-P~lepB~, SPAM15C-P~gln *E*~, SPAM17C-P~Rv2466c~, SPAM18C-P~Rv2745c~, SPAM20C-P~senX3~, and SPAM23C-P~trpD~.](id-2016-00075g_0002){#fig1}

We monitored growth of each strain in a tube and microplate format. Growth defects were seen with the underexpressing strains, which were more pronounced in 96-well plates when compared to wild-type. Small growth defects were seen in aerated liquid medium when grown in tubes except for SPAM19C, which showed a significant growth defect ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}a). However, larger defects were seen in 384-well plates where SPAM17C and SPAM18C showed a significant delay in growth ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}b). Two strains (SPAM13C and SPAM15C) showed an intermediate growth phenotype with a slower growth rate than that of the wild-type. We measured the signal to background (S:B) for each strain. At day 5 all strains had S:B \> 5, which is sufficient for screening. We selected SPAM13C for HTS assay development because it showed both lower levels of expression and a slight growth defect.

![Growth of *M. tuberculosis* strains in aerobic culture. *M. tuberculosis* strains were grown in (a) growth tubes (data are the average ± standard deviation of three independent cultures) and (b) 384-well plates (data are the average ±standard deviation of all wells in the plate). Strains of *M. tuberculosis* expressing codon-optimized mCherry were wild-type H37Rv CHEAM3 (■), and strains expressing LepB under the control of different promoters were SPAM13C-P~lepB~ (△), SPAM15C-P~gln *E*~ (□), SPAM17C-P~Rv2466c~ (◇), SPAM18C-P~Rv2745c~ (○), SPAM19C-P~Rv2930~ (▽), SPAM20C-P~senX3~ (×), and SPAM23C-P~trpD~ (+).](id-2016-00075g_0003){#fig2}

HTS Assay Development {#sec2.2}
---------------------

We adapted our previous 96-well assay format for *M. tuberculosis* growth^[@ref19]^ to a 384-well format for single-point screening for both wild-type and SPAM13C (LepB-UE) strains. We varied a number of parameters to determine optimum assay conditions, which included bacterial cell density, length of assay, assay volume, and DMSO concentration. The assay was validated using standard robustness testing to determine interplate and interday variability according to NCGC guidelines.^[@ref20]^ The assay was run three times independently using conditions to produce minimum, midpoint, and maximum signals in duplicate. Statistical analysis was used to confirm that reproducibility met the appropriate criteria; *Z*′ factor \> 0.5 and % CV \< 20% were attained, indicating a robust and reproducible assay (values were *Z*′ 0.76--0.87; % CV 3.4--7.0). Maximum assay robustness and reproducibility were attained with the following assay conditions: 10 μL of bacterial culture at an OD~590~ = 0.06 and 20 μL of compound in 384-well plates incubated for 5 days at 37 °C. The final DMSO concentration was 2%, and the final compound concentration was 20 μM, respectively.

Primary Screen {#sec2.3}
--------------

We screened a library of ∼72,000 diverse small molecules from our library (from ChemBridge) against both wt and the LepB-UE strains at 20 μM. Using a cutoff of 95% inhibition, the hit rate against the LepB-UE strain was 1.7% (1252 compounds), which was higher than the hit rate against the wt (1.3%, 949 compounds) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Of the 1252 compounds active against LepB-UE, 121 displayed greater activity as compared to the wt strain.

![Primary screen. About 72,000 compounds were tested for inhibition of growth at a fixed concentration of 20 μM against wild-type and LepB-UE (SPAM13C) strains. Strains were grown in 384-well plates for 5 days in the presence of compound. Data are the percent growth inhibition compared to controls. A threshold for hits was set at 95% inhibition against either strain (highlighted in the bold boxes).](id-2016-00075g_0004){#fig3}

One hundred and eighty-nine compounds that inhibited growth ≥95% in either strain or that differentially inhibited the underexpressing LepB strain were selected for follow-up. Of this set, 21 compounds had a minimum inhibitory concentration (MIC) ≤ 20 μM against the LepB-UE strain and were also at least 2-fold more potent against the LepB-UE strain than the wt strain. Of these differential hits, 19 (**1**--**19**) belonged to the phenylhydrazone (PHY) class; compound **1** was the most potent ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Although there was only a single 1:1 comparator to compound **1**, the MICs revealed that different substitutions around the hydrazone moiety, including fused rings (**5**--**8**), acylhydrazones (**11**--**15**), picolinimidohydrazides (**16**, **17**), hydrazinecarbothioamide (**18**), and hydrazinecarbodithioate (**19**), were tolerated.

###### Biological Profile of PHY Compounds Identified from the Primary Screen

![](id-2016-00075g_0007){#fx1}

LepB-UE MIC values are minimum inhibitory concentrations (MIC) for *M. tuberculosis* strain SPAM13C. MICs are the average ± standard deviation of at least of two independent experiments unless otherwise noted.

Single MIC values were obtained.

Wild-type (wt) MIC are for *M. tuberculosis* strain. MICs are the average ± standard deviation of at least of two independent experiments unless otherwise noted.

CC~50~ is the concentration required to inhibit Vero cells by 50%.

Not determined.

Phenylhydrazone Structure--Activity Relationship (SAR) {#sec2.4}
------------------------------------------------------

Hydrazones possess a wide range of pharmacological properties, including antimicrobial,^[@ref21]−[@ref23]^ antitubercular,^[@ref24]−[@ref31]^ anti-inflammatory,^[@ref32]^ and anticancer^[@ref33]−[@ref35]^ activities. Hydrazone compounds that are derivatives of isoniazid or pyrazinamide have been reported with some activity against *M. tuberculosis*.^[@ref24]−[@ref31]^ The compounds we identified in our primary screen (**1**--**19**) and the analogues for the PHY series (**20**--**42**) had some structural similarity to isoniazid, but the pyrazole and picolinohydrazide derivatives (**43**--**56**) did not.

We selected the PHY series for further evaluation to see if we could improve potency and cytotoxicity. From our primary screen, compound **1** was the most active against the LepB-UE strain and was selected for limited SAR analysis to gain insight into the structural requirements for activity ([Tables [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} and [4](#tbl4){ref-type="other"}); 30 compounds were purchased commercially, and 8 compounds were synthesized and tested.

###### Biological Profile of Analogues of Compound 1

![](id-2016-00075g_0008){#fx2}

![](id-2016-00075g_0009){#fx3}

LepB-UE MIC values are minimum inhibitory concentrations (MIC) for *M. tuberculosis* strain SPAM13C. MICs are the average ± standard deviation of at least of two independent experiments unless otherwise noted.

Single MIC values were obtained.

Wild-type (wt) MICs are for *M. tuberculosis* strain. MICs are the average ± standard deviation of at least of two independent experiments unless otherwise noted.

CC~50~ is the concentration required to inhibit Vero cells by 50%.

Not determined.

###### Biological Profile for Pyrazole and Picolinohydrazide Derivatives

![](id-2016-00075g_0010){#fx4}

LepB-UE MIC values are minimum inhibitory concentrations (MIC) for *M. tuberculosis* strain SPAM13C. MICs are the average ± standard deviation of at least of two independent experiments unless otherwise noted.

Single MIC values were obtained.

Wild-type (wt) MICs are for *M. tuberculosis* strain. MICs are the average ± standard deviation of at least of two independent experiments unless otherwise noted.

CC~50~ is the concentration required to inhibit Vero cells by 50%.

Not determined.

We first focused on activity against the LepB-UE strain (SPAM13C). Three segments of compound **1** (R~1~, R~2~, R~3~) were examined ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). Replacement of pyridine at R~1~ with a furan (**20**), thiophene (**21**), phenyl (**22**), or phenol (**23**, **24**) reduced the potency at least 10-fold (MIC = 30--90 μM), whereas activity was abolished with methyl (**25**) or pyridine (**26**) replacements. R~1~ and R~3~ substitutions with a phenyl group (**27**) had little impact on antitubercular activity compared to compound **1**.

Replacement of the 4,6-dimethylpyrimidine with a pyridine at R~2~ (**29**) resulted in a 42-fold decrease in potency; however, activity was comparable to that of **1** when R~2~ was substituted with either a triazinoindole (**28**), picolinimidohydrazide (**30**), or acylhydrazone (**31**) moiety. The potency of three additional picolinimidohydrazide (**32**--**34**) and six acylhydrazone derivatives (**35**--**40**) was examined. With the exception of **33**, the picolinimidohydrazide derivatives were moderately active (MIC = 41--106 μM). Two of the most potent compounds from the PHY series were acylhydrazone derivatives (**37** and **39**) with MICs of 2--2.5 μM. Activity to comparable to that of **1** was observed when the R~2~ group was replaced with a thioamide (**41**); however, a 16-fold decrease in activity was observed when it was replaced with a benzenesulfonyl group (**42**). Our data suggest that the R~1~ position is rather sensitive to modifications and the pyridine group is the preferred functionality at R~1~. The R~2~ position tolerates a larger range of substitutions, and at the R~3~ position, the methyl and phenyl groups were preferred. The data also suggest that the acylhydrazone moiety as seen in compounds **11**--**15**, **31**, **35**, **37**--**40**, and **57** is well tolerated, with MIC values in the range of 3.5--15 μM.

To explore the impact of the hydrazone moiety upon activity, several substituted pyrazoles (**43**--**56**) and a picolinohydrazide (**57**) derivatives were tested ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). Whereas the picolinohydrazide (**57**) exhibited activity similar to that of **1**, other pyrazole derivatives were detrimental to the antitubercular activity (MIC = 44--95 μM) or had no activity (MIC \> 200 μM). We tested our compounds at a relatively high concentration (200 μM). Because our assay used a dual readout---both OD and RFU---we are able to identify solubility issues in the medium, normally seen as a discordance between the readouts. We did not see any issues with solubility in the microbiological medium that interfered with the measurement of growth used to determine MICs for the compounds tested.

Differential Activity {#sec2.5}
---------------------

We were interested in finding compounds that targeted the secretory machinery and were potent against the wt strain. To determine if our series was truly active in this mechanism, we determined the activity against the wt strain and compared this to the LepB-UE strain. Differential activity, defined as \>2-fold difference in MIC, was observed for 36 of 57 compounds ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a; [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}--[[4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). In many cases the differences were small and the MICs were repeated multiple times to confirm the difference. For MICs where the difference was \<10-fold, they were repeated a minimum of four times; for MICs with a differential of \>10-fold, they were repeated twice. The differential we observed was consistent with an effect on LepB, because our expression levels were reduced by approximately 4-fold, such that we would not expect to see larger shifts in MIC.

![Correlation between potency, cytotoxicity, and biochemical activity. Plots of (a) pMIC LepB-UE versus pMIC wt for 58 PHY compounds and (b) pMIC LepB-UE versus plC50 purified membrane fractions for 32 PHY compounds. Compounds were selected for evaluation in the biochemical assay according to the established criteria (%I \> 40). (c) Plot of pMIC LepB-UE versus plC~50~ Vero cells for 58 compounds. The limit of detection, as indicated by the dashed line, is 200 μM for both the cellular and biochemical assays and 100 μM for the cytotoxicty assay involving Vero cells.](id-2016-00075g_0005){#fig4}

Compounds **5**, **8**, **10**, **14**, **15**, **17**, and **28** exhibited a differential \>10, with compound **8** being 56-fold more potent toward the LepB-UE strain, and in fact all were inactive against the wt strain (MICs \> 200 μM). The hydrazinecarbothioamide derivative (**41**), on the other hand, was equally potent toward both wt and LepB-UE.

Compounds **11** and **39** exhibited differential activity, but were also active against the wt strain with an MIC \< 10 μM. Larger sets of analogues based on compounds **11** and **39** are needed to gain insight into the tolerability of the R~2~ position.

LepB Activity Assay {#sec2.6}
-------------------

The increased sensitivity of the LepB-UE strain to the PHY series could be due to a direct inhibitory effect on LepB, an effect on other components of the secretory pathway, or inhibition of a secreted protein. We wanted to determine if the series directly inhibits LepB. Purified active LepB is not available. We made substantial attempts to produce active protein in multiple expression systems, but were unable to produce active folded protein (data not shown). LepB is an integral membrane protein, and its activity may be dependent on its correct folding within the membrane; therefore, we used purified membrane fractions to develop an in vitro assay for signal peptide cleavage. We used an internally quenched synthetic peptide substrate as the probe; cleavage of the peptide leads to fluorescence.^[@ref36]^ This assay has been used extensively to characterize the activity of various SPases from *Escherichia coli*, *Staphylococcus aureus*, and *Staphylococcus epidermidis*.^[@ref36]−[@ref38]^

We monitored peptide cleavage in the presence of selected compounds. MD3, a known inhibitor of LepB ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.6b00075/suppl_file/id6b00075_si_001.pdf) Figure S1), was used as a control. In this assay MD3 has an IC~50~ of 12 μM. Of the 57 compounds tested, 32 inhibited LepB activity by ≥40% at 200 μM (data not shown). We determined the IC~50~ for each active compound ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b; [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}--[[4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). Of the 36 differentially active compounds, 10 had an IC~50~ \< 150 μM in the biochemical assay, with compound **3** being the most active with an IC~50~ of 12 μM.

We did not see a correlation between the whole cell assay and the membrane assay ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). Our secretion assay was based on membrane fractions that could have other membrane proteins, lipids, and phospholipids present in higher relative amounts than in the whole cells, which could account for a lack of activity in this assay. Additionally, compounds that lack activity at the biochemical level could target other components of the secretory pathway or a secreted protein. We tested our compounds for activity against the unrelated protein IspC (Dxr), which catalyzes the second step in the non-mevalonate pathway of isoprenoid biosynthesis. IspC has a metal-dependent activity and has 10% sequence identity to LepB. No inhibition of IspC was seen (data not shown), suggesting that the compounds are not acting via nonspecific mechanisms.

Activity against Overexpressing Strain {#sec2.7}
--------------------------------------

We tested several compounds for activity against a LepB overexpressing strain. If compounds target LepB, we would expect that the overexpressing strain would be more resistant. We would be less likely to see this shift if compounds were targeting a secreted protein downstream, because overexpression of LepB would not affect the amount of the target protein produced. Eight differentially active compounds along with MD3 were tested against the LepB overexpressing strain (LepB-OE) ([Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}). MD3 has MICs of 7.5 and 27 μM against the LepB-UE and wt, respectively. When tested against the LepB-OE, an MIC of 35 μM was attained.

###### Comparison of MICs against Different Strains

  compound   LepB-UE MIC[a](#t5fn1){ref-type="table-fn"} (μM)   WT MIC[b](#t5fn2){ref-type="table-fn"} (μM)   LepB-OE MIC[c](#t5fn3){ref-type="table-fn"} (μM)
  ---------- -------------------------------------------------- --------------------------------------------- --------------------------------------------------
  **1**      3.0 ± 1.1                                          18 ± 1                                        18 ± 8
  **2**      9.3 ± 3.2                                          43 ± 26                                       160 ± 57
  **11**     3.5 ± 1.8                                          14 ± 7                                        5.6 ± 0.6
  **27**     2.2 ± 0.7                                          17 ± 8                                        103 ± 38
  **30**     7.7 ± 0.2                                          47 ± 6                                        \>200
  **38**     4.9 ± 0.2                                          17 ± 5                                        9.2 ± 4.0
  **39**     2.5 ± 0.2                                          5.5 ± 1.4                                     6.5 ± 2.2
  **40**     15 ± 1                                             42 ± 15                                       27 ± 2

LepB-UE MIC values are minimum inhibitory concentrations (MIC) for *M. tuberculosis* strain SPAM13C. MICs are the average ± standard deviation of at least of two independent experiments unless otherwise noted.

Wild-type (wt) MICs are for *M. tuberculosis* strain. MICs are the average ± standard deviation of at least of two independent experiments unless otherwise noted.

LepB-OE MICs are for *M. tuberculosis* strain expressing LepB under the hsp60 promotor. MICs are the average ± standard deviation of at least of two independent experiments unless otherwise noted.

In particular compounds **2**, **27**, and **30** showed a clear pattern of decreased activity as LepB expression levels increased from the LepB-UE to the wt to the LepB-OE strain. All compounds showed a difference between at least two strains. This adds weight to our hypothesis that the compounds are targeting LepB directly. The lack of a linear relationship between MIC in the three strains could result from a number of reasons, because MICs measure the outcome of a number of parameters, which include compound penetration to the target, binding efficiency, off-rate of binding, and efflux. Measurements are complicated by the fact that inhibition of LepB itself is likely to affect permeability and cell wall composition, and this could directly affect compound efficacy. However, the trends seen across the series increase our confidence that there is a bona fide inhibition.

Membrane Permeability Assay {#sec2.8}
---------------------------

To determine whether compound treatment increased membrane permeability, we examined the accumulation of ethidium bromide ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). Interestingly, LepB-UE was slightly more permeable as compared to the wild-type, suggesting some alterations in cell wall structure. The small increase in permeability did not significantly affect sensitivity to rifampicin: MICs of 7.7 ± 2.3 nM against wt and 5.4 ± 0.9 nM against LepB-UE. However, treatment with PHY analogues did not change permeability, either in the wild-type or in the LepB-UE strain. Thus, the compounds had no direct effect on permeabilizing bacterial cells. We also looked at the effect of compounds on membrane potential, but none of the compounds had any effect ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.6b00075/suppl_file/id6b00075_si_001.pdf) Figure S2).

![Permeability of *M. tuberculosis* strains. Permeability was assessed by monitoring uptake of ethidium bromide. Strains were exposed to compounds, MD3 (control), or untreated. Each assay was carried out twice. Data are the mean ± SD.](id-2016-00075g_0006){#fig5}

Selectivity {#sec2.9}
-----------

We looked at the selectivity of the PHY series for bacterial cells. Most compounds had some level of cytotoxicity against Vero cells with low selectivity index (SI \< 3) ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}c; [Tables [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}--[[4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). One compound (**16**), a picolinimidohydrazide derivative, had SI \> 10, suggesting potential for improvement. The activity of additional picolinimdioylhydrazide derivatives was evaluated. Substituting the R~1~ hydroxyl group of **16** with either a hydrogen (**34**) or a methoxy (**33**) group resulted in a 15-fold decrease in selectivity. The observed decrease in selectivity for these compounds was the result of a decrease in potency against the LepB-UE concomitant with a loss of activity against the wt strain. Whereas the removal of the R~1~ nitro group from **16**, as seen with compound **17**, had little impact upon potency against LepB-UE and cytotoxicity, a ∼4-fold increase in potency against wt was observed. Differentially active compound **57** also had SI \> 10 and was active against wt (MIC = 25 μM). We need additional SAR evaluation to understand how chemical modification around the hydrazone moiety directly influences the potency and selectivity.

Conclusion {#sec3}
==========

We developed and implemented a high-throughput screen using an *M. tuberculosis* strain engineered with reduced LepB expression to allow the identification of weak inhibitors of *M. tuberculosis* growth. We identified the PHY series that was more potent against the LepB-UE strain than against the wt strain. We conducted a focused SAR study and determined that we were able to generate compounds with activity against the wt strain, which also retained the differential activity. Thus, our strategy of starting with "weak" inhibitors selected by the LepB-UE was validated. The PHY series had differential activity against recombinant LepB strains and demonstrated inhibition of LepB in a membrane fraction assay. Furthermore, we did not observe an increase in ethidium bromide accumulation for wt or Lep-UE strains upon treatment with a select number of PHY compounds. Taken together, this suggests the possibility that the series targets LepB directly, rather than a downstream secreted protein or by increased permeability due to cell wall alteration. Cytotoxicity was a problem with this series, although we identified one compound with good selectivity, suggesting a path forward. Future work to progress the PHY series into lead compounds would address cytotoxicity/selectivity as well as confirm the mode of action on LepB.

Methods {#sec4}
=======

Bacterial Culture {#sec4.1}
-----------------

The *M. tuberculosis* strains and plasmids used in this study are summarized in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. All strains were maintained in Middlebrook 7H9 medium supplemented with 0.5% w/v Tween 80 and 10% v/v oleic acid albumin dextrose catalase (OADC) supplement (7H9-Tw-OADC) or on Middlebrook 7H10 agar plus 10% v/v OADC. Hygromycin B was added to 50 μg/mL when necessary.

Construction of Recombinant *M. tuberculosis* Strains {#sec4.2}
-----------------------------------------------------

Several expression plasmids were constructed in which LepB was placed under the control of different promoters. A native expression construct with *LepB* under the control of its native promoter (pUPPY13) was made by PCR amplification using primer pair P1lepB-F1 5′ [CGA ATT C]{.ul}CT GTA CTA CCT GCG CGA A 3′ and PlepB-R 5′ [CAG GGC GCC ACT ACT A]{.ul}AT GGC TAC CGA CCT TGC T 3′ and subcloning into pINT7 as *Eco*RI and *Kas*I fragments. The LepB gene was amplified using primer pair NPlepB_F1 5′ AAG CTT GTG ACC GAA ACC ACG GAC TC 3′ and NPlepB_R3 5′ CGT CGA CTA CTA ATG GCT ACC GAC CTT GC 3′ and cloned into promoter-expression constructs containing P~senX~, P~trpECBA~, P~trpD~, P~gln*E*~, P~Rv0251c~, P~Rv2466c~, P~Rv2745c~, P~Rv2930~, P~Rv0967~, or P~mbtl~ in an integrating plasmid based on pSM128 (containing the L5 integrase, attP site, and SmR) by replacing the LacZ with LepB (*Hin*dIII--*Sal*I fragment).^[@ref39]^

*M. tuberculosis* strains were constructed by gene switching.^[@ref17]^ A strain of *M. tuberculosis* in which a functional LepB (under the control of a tetracycline-inducible promoter) was provided on an integrating plasmid (HygR) and the normal chromosomal copy was deleted (in-frame, unmarked deletion) was used.^[@ref2]^ Expression plasmids carrying LepB under the control of various heterologous promoters together with the L5 integrase/attP site and streptomycin resistance gene (SmR) were constructed. Each plasmid was switched into the del-int strain by electroporation and selection on streptomycin; replacement of the resident plasmid was confirmed by testing for hygromycin sensitivity.

A LepB overexpressing strain (LepB-OE) was constructed by electroporating pOPPY4, an expression plasmid in which *lepB* was under the control of the hsp60 promoter,^[@ref2]^ into *M. tuberculosis* H37Rv.

Measurement of LepB mRNA Transcripts {#sec4.3}
------------------------------------

Total *M. tuberculosis* RNA was extracted as previously described.^[@ref40]^ A two-step quantitative reverse transcriptase PCR using the TaqMan Gene Expression Master Mix (ThermoFisher Scientific) was performed according to the manufacturer's instructions using *lepB* and *sigA* specific primer--probe sets: *lepB*-TaqManF1 (5′-GGT GCT GGC GGT GAT TG-3′), *lepB*-TaqManR1 (5′-AAG GGC GCG CGA CAA-3′), and *lepB*-MGB probe (5′-AAG GGC GCG CGA CAA-3′); *sigA*-TaqMan F1 (5′-CCG ATG ACG ACG AGG AGA TC-3′), *sigA*-TaqMan R1 (5′-GGC CTC CGA CTC GTC TTC A-3′), and *sigA*-MGB probe (5′-CCT CCG GTG ATT TC-3′). Transcript copy numbers were calculated using standard curves for each gene generated with genomic DNA. Controls including no RT reaction were used to control for DNA contamination. The transcript level of *lepB* was normalized to the transcript levels of *sigA*, a housekeeping sigma factor.^[@ref41]^

HTS and MIC Determination {#sec4.4}
-------------------------

A chemically diverse small molecule library from ChemBridge was screened against the wt and LepB-UE strains. Compounds were diluted to 1 mM in DMSO and screened at a final concentration of 20 μM. Fluorescent strains of *M. tuberculosis* expressing codon-optimized mCherry were generated by electroporating pCherry10^[@ref42]^ into wt and recombinant strains. Strains were grown in 7H9-OADC-Tw to an OD~590~ of 0.8--0.9 and diluted to a theoretical OD~590~ of 0.06. The assay conditions for screening were as follows: 10 μL of culture was dispensed into black, clear-bottomed 384-well microplates containing 20 μL of 7H9-Tw-OADC-DMSO containing test compound (final DMSO and compound concentrations of 2% and 20 μM, respectively). Plates were incubated for 5 days at 37 °C in high humidity, and growth was monitored by OD~590~ and/or fluorescence (Ex 589 nm/Em 614 nm).^[@ref19]^ Each assay plate included controls in columns 1, 2, 23, and 24 as follows: columna 1 and 23, maximum inhibition (2 μM rifampicin); column 2, minimum inhibition (2% DMSO); column 24, contamination control (no inoculum). Results were analyzed and managed using the Web-based software from the Collaborative Drug Discovery (CDD). The % CV and *Z*′ values for each assay plate were calculated.

MICs were determined against wt, LepB-UE, and LepB overexpressing (LepB-OE) strains according to published methods.^[@ref19]^ A 10-point 2-fold serial dilution was carried out on each of compounds from a starting concentration of 10 mM such that the final assay concentration ranged from 200 μM to 10 nM. Bacterial growth was measured by OD~590~ after 5 days of incubation at 37 °C in 96-well, black, clear-bottomed plates. Results were analyzed and managed using the Web-based software from the Collaborative Drug Discovery (CDD). A nonlinear least-squares curve was generated to calculate the MICs. The dose--response experiment was carried out at least four times for those compounds with a differential activity between 2 and 10 and at least two times for those with a differential activity \>10.

LepB Membrane Assay {#sec4.5}
-------------------

Cell membrane fractions were isolated from γ-irradiated whole *M. tuberculosis* H37Rv (NR-14819; BEI resources). Cells (10 g) were washed once in 100 mL of 20 mM Tris (pH 8.0), 250 mM NaCl, and 0.05% w/v Tween 80 buffer and suspended in 80 mL of 20 mM Tris, pH 8, and 1% Triton X-114. The suspension was incubated for 1 h with rotation, and the pellet was recovered by centrifugation. One hundred milligrams of Triton X-114 membrane fraction pellet was solubilized in 1 mL of XTractor buffer (Clontech) and transferred to a 2 mL screw-cap tube containing 0.1 mm silica. The tubes were agitated in a BeadBeater (BioSpec) for five 30 s pulses. The resulting cell membrane fraction was diluted 1:5 with 50 mM Tris-HCl, pH 8.0, and assayed for SPase activity using the fluorogenic peptide substrate 3-nitrotyrosine (NO)-YFSASALA∼KI-aminobenzoic acid-OH (ABZ) (California Peptide). Assays were performed in 96-well black plates with 2 μM substrate, 200 μM test compound, and 3% DMSO in 50 mM Tris-HCl, pH 8.0 (total volume = 100 μL). Reactions were initiated by the addition of 10 μL of cell membrane fraction and incubated at 37 °C for 4 h. Activity was analyzed by fluorescence (Ex 315 nm/Em 410 nm). Each assay plate contained controls with no compound or no cell membrane fraction. Dose--response was carried out for all compounds exhibiting an inhibition of ≥40%.

Membrane Permeability {#sec4.6}
---------------------

Cell permeability was assessed by monitoring uptake of ethidium bromide.^[@ref43]^ Strains were grown to an OD~590~ of 0.8--0.9, harvested, washed three times in PBS and 0.05% w/v Tween 80, and resuspended in PBS and 0.05% w/v Tween 80 buffer to a final OD~590~ of 0.8. Aliquots (50 μL) were dispensed into black, clear-bottomed, 96-well microplates containing 50 μL of PBS, 0.05% w/v Tween 80, 8 μg/mL ethidium bromide, and test compound (final DMSO and compound concentrations of 2% and 200 μM, respectively). The accumulation of EtBr was determined by monitoring the increase in fluorescence (Ex 530 nm/Em 590 nm) over a 90 min period while the plates were incubated at 37 °C.

Membrane Potential {#sec4.7}
------------------

Membrane potential was determined using the cationic dye DiOC~2~. Cells were grown to an OD~590~ of 0.8--0.9, harvested, and washed three times in 7H9 lacking OADC. Bacteria were resuspended in 7H9 (no OADC) to an OD~590~ of 1, incubated with DiOC~2~ for 20 min at room temperature, and harvested. Bacteria were resuspended in the same volume of 7H9 (no OADC) and aliquoted (50 μL) into black, clear-bottomed, 96-well microplates containing 50 μL of medium and test compound (final DMSO and compound concentrations of 2% and 200 μM, respectively). Cells were incubated at room temperature for 45 min, fluorescence was measured at Ex 488 nm/Em 530 nm and Ex 488 nm/Em 610 nm, and the ratio was calculated.

Cytotoxicity {#sec4.8}
------------

Cytotoxicity against African green monkey adult kidney cell (Vero cells) was determined as previously described using CellTiter-Glo reagent.^[@ref44]^ The concentration causing 50% growth inhibition (IC~50~) was calculated by fitting the inhibition curves using the Levenberg--Marquardt algorithm.

Chemical Synthesis {#sec4.9}
------------------

The synthesis of phenylhydrazones (PHY) was achieved by dissolving 1 equiv of the acid with 1 equiv of the hydrazine in anhydrous ethanol. After refluxing the reaction overnight, the acetone was evaporated off, and the crude reaction mixture was purified by column chromatography. ^1^H and NMR spectral data were recorded in CDCl~3~ or acetone-*d*~6~ on a 300 MHz Bruker NMR spectrometer. Column chromatography was conducted on Revelaris flash chromatography system. Reactions were monitored using thin-layer chromatography (TLC) on silica gel plates. HPLC analysis was conducted on an Agilent 1100 series LC system (Agilent ChemStation Rev.A.10.02; Phenomenex-Luna-C18, 4.8 mm × 150 mm, 5 μm, 1.0 mL/min, UV 254 nm, room temperature) with MeCN/H~2~O (0.05% TFA or HCOOH buffer) gradient elution. HPLC-MS was performed on a Gilson 321 HPLC with detection performed by a Gilson 170 DAD and a Finnigan AQA mass spectrometer operating in electrospray ionization mode using a Phenomenex Gemini C18 150 × 4.6 mm column. Unless noted, all chemicals were purchased pure, from commercially available sources such as Sigma-Aldrich, Enamine, Chembridge, Fisher, or other chemical vendors. All reagents and solvents were used as received. Compounds **25**, **27**, **29**, **33**, **34**, **42**, and **58** are known compounds that can be purchased commercially. Compounds **30**,^[@ref45]−[@ref47]^**32**,^[@ref48]^ and **42**([@ref49],[@ref50]) were prepared according to modified literature procedures.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsinfecdis.6b00075](http://pubs.acs.org/doi/abs/10.1021/acsinfecdis.6b00075).Figure S1, structure and activity of MD3; Figure S2, impact of compounds on membrane potential ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.6b00075/suppl_file/id6b00075_si_001.pdf))
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